UBS Group
BCYC

UBS Group’s Bicycle Therapeutics BCYC Stock Holding History

UBS Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.5K Sell
15,459
-16,700
-52% -$76.6K ﹤0.01% 7431
2026
Q1 		$149K Buy
32,159
+6,483
+25% +$37K ﹤0.01% 6792
2025
Q4 		$182K Buy
25,676
+14,303
+126% +$105K ﹤0.01% 6630
2025
Q3 		$88K Sell
11,373
-22,002
-66% -$166K ﹤0.01% 7213
2025
Q2 		$232K Sell
33,375
-39,327
-54% -$313K ﹤0.01% 6624
2025
Q1 		$617K Sell
72,702
-59,659
-45% -$703K ﹤0.01% 5690
2024
Q4 		$1.85M Buy
132,361
+120,295
+997% +$2.58M ﹤0.01% 4789
2024
Q3 		$273K Sell
12,066
-3,869
-24% -$89.3K ﹤0.01% 5645
2024
Q2 		$323K Buy
15,935
+5,953
+60% +$134K ﹤0.01% 5328
2024
Q1 		$249K Sell
9,982
-1,168
-10% -$24.8K ﹤0.01% 5700
2023
Q4 		$202K Sell
11,150
-155
-1% -$2.56K ﹤0.01% 5778
2023
Q3 		$227K Sell
11,305
-1,307
-10% -$29.9K ﹤0.01% 5277
2023
Q2 		$322K Sell
12,612
-1,280
-9% -$29.7K ﹤0.01% 5165
2023
Q1 		$295K Buy
13,892
+950
+7% +$23.8K ﹤0.01% 5093
2022
Q4 		$383K Sell
12,942
-15,533
-55% -$417K ﹤0.01% 4931
2022
Q3 		$662K Buy
28,475
+15,509
+120% +$369K ﹤0.01% 4102
2022
Q2 		$218K Buy
12,966
+4,082
+46% +$86.1K ﹤0.01% 4839
2022
Q1 		$389K Buy
8,884
+7,992
+896% +$373K ﹤0.01% 4864
2021
Q4 		$54K Buy
892
+46
+5% +$2.54K ﹤0.01% 6820
2021
Q3 		$35K Sell
846
-869
-51% -$30.4K ﹤0.01% 6613
2021
Q2 		$52K Buy
1,715
+1,363
+387% +$41.2K ﹤0.01% 6391
2021
Q1 		$11K Buy
352
+118
+50% +$3.04K ﹤0.01% 7846
2020
Q4 		$4K Sell
234
-261
-53% -$5.04K ﹤0.01% 7895
2020
Q3 		$9K Sell
495
-1,790
-78% -$31.6K ﹤0.01% 6916
2020
Q2 		$36K Buy
+2,285
New +$35.1K ﹤0.01% 6134
2019
Q3 		– Sell
-1,718
Closed -$17K – 7990
2019
Q2 		$17K Buy
+1,718
New +$20.7K ﹤0.01% 6721

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS Group's BCYC Position: Q2 2026 in Review

UBS Group reduced its Bicycle Therapeutics (BCYC) stake by 52% in Q2 2026, selling an estimated $76.6K and leaving 15,459 shares worth $65.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7431.

UBS Group first reported a position in BCYC in Q2 2019 and has held it in 26 quarters since. The position peaked at $1.85M in Q4 2024. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • UBS Group held 15,459 shares of Bicycle Therapeutics worth $65.5K as of Q2 2026.
  • UBS Group sold 16,700 Bicycle Therapeutics shares in Q2 2026, an estimated $76.6K.
  • Bicycle Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7431 holding.
  • UBS Group first reported a position in Bicycle Therapeutics in Q2 2019 and has held it in 26 quarters since.
  • UBS Group's Bicycle Therapeutics position peaked at $1.85M in Q4 2024.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.